Trevi Therapeutics News and Activities
Presence
Trevi Therapeutics develops medicines for serious neurologic and respiratory conditions. Its products and research services focus on chronic cough and itch disorders for patients, healthcare providers, and clinical partners.
Trevi Therapeutics products and services overview:
- Drug development
- Clinical research
- Chronic cough therapies
- Itch disorder therapies
Revenue: ~$0 million
Employees: 40
Headquarters: New Haven, United States (USA)
Trevi Therapeutics is one of the...
Trevi Therapeutics is a company listed under the stock ticker TRVI (US).
Acquisition, funding and merger involving Trevi Therapeutics.
- Trevi Therapeutics has just announced a $150 Million fundraising (posted on April 20 2026).
Executives
View the org chart displaying its 24 main executives
Most searched biographies at Trevi Therapeutics
- Jennifer Good, Director, President and Chief Executive Officer
- Anne VanLent, Director
- Michael Heffernan, Director
Popular executive movements at Trevi Therapeutics
- David Hastings will join the company as Chief Financial Officer on Jan. 6, 2026 (posted on December 5 2025).
Create your alert
to follow the executive moves at Trevi Therapeutics.
Biotechnology
Trevi Therapeutics has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Trevi Therapeutics
- Press Releases | Trevi Therapeutics, Inc.
- Press Releases | Trevi Therapeutics, Inc.
- Press Releases | Trevi Therapeutics, Inc.
- Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates | May 5, 2026
- Press Releases | Trevi Therapeutics, Inc.
- Press Releases | Trevi Therapeutics, Inc.
- Trevi Therapeutics to Participate in Upcoming May Events | April 23, 2026
- Trevi Therapeutics Announces Proposed Public Offering of Common Stock | April 16, 2026
- Press Releases | Trevi Therapeutics, Inc.
- Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares | April 20, 2026
- View more press releases Close
Social media about Trevi Therapeutics
- Trevi Therapeutics on Wikipedia, Google News & Yahoo Finance
- Trevi Therapeutics on LinkedIn, X (Twitter) & YouTube
